Search Results
Aug 20, 2026, 02:00 ET Supreme Infrastructure Targets Next-Phase Growth Led by EPC, Housing & GCC Projects
decades: buildings. While infrastructure remains at the core of its business, the company is seeing renewed opportunity in building construction and RCC frame structures, areas where it has an established execution track record. With a strong foundation in EPC, the focus now is on putting these capabilities
More news about: Supreme Infrastructure India Limited
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
that have progressed despite prior checkpoint inhibitor therapy, with a primary focus on non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Clinical findings suggest that the combination may help overcome acquired resistance to PD-1 inhibitors by reducing immunosuppressive myeloid-cell
More news about: DelveInsight Business Research, LLP
Aug 19, 2026, 05:00 ET NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product
review of a New Drug Application (NDA).Clear cell renal cell carcinoma is the most common subtype of renal cell carcinoma (RCC), accounting for approximately 70%–80% of RCC cases. According to the American Cancer Society, in 2026, an estimated 80,450 new cases of kidney (renal) cancer will be diagnosed
More news about: Norroy Bioscience Co., Ltd.
Aug 11, 2026, 10:07 ET EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
call, Chief Executive Officer Michael Morrissey described CABOMETYX as continuing "to grow in revenue, demand, and market share as the leading TKI for RCC and the market leader for neuroendocrine tumors in the oral second-line plus segment." Second-quarter revenue came in at approximately $628.7 million.Investors
More news about: SueWallSt.com
Aug 10, 2026, 18:19 ET Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)
investors Exelixis was "off to a strong start in 2026" and that CABOMETYX "continued to grow in revenue, demand, and market share as the leading TKI for RCC and the market leader for neuroendocrine tumors in the oral second-line plus segment."When the Company subsequently reduced its full-year 2026
More news about: Levi & Korsinsky, LLP
Jul 16, 2026, 09:00 ET Five Community Colleges Launch Ambitious Redesign Plans to Meet the Needs of a New Economy
from design into implementation, focused on aligning teams, testing new approaches and strategies, and measuring progress towards ambitious goals. The RCC Design Challenge builds on the Lab's
More news about: Education Design Lab
Jun 30, 2026, 09:00 ET AVEO Oncology Announces Succession Plan
adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet
More news about: AVEO, an LG Chem company
Jun 10, 2026, 08:05 ET Interwell Health Delivers Strong Quality Scores and Shared Savings in CMS Value-Based Kidney Care Model
practices in the CKCC with resources including embedded renal care coordinators (RCCs), clinical documentation support, and advanced analytics. "Without an RCC I don't know how this program would work, because the RCCs do so much in terms of increasing optimal starts and engaging family members," said Dr. William
More news about: Fresenius Medical Care Holdings, Inc.
Jun 02, 2026, 07:00 ET Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
More news about: Evogene
May 27, 2026, 09:40 ET Captive Radiology Secures Growth Investment to Accelerate Expansion and Enhance Patient Care Nationwide
www.captiveradiology.com.About RC CapitalRCC is focused on building high-growth businesses that empower sustainable change in healthcare. We seek to be a business partner first and a capital provider
More news about: Captive Radiology
May 22, 2026, 08:30 ET Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence
PM–4:30 PM CDT. Location: Hall A, Poster: 279.Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 150 RCC patients. (Abstract 4541) Session: Genitourinary Cancer—Kidney and Bladder. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM
More news about: Caris Life Sciences
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
dose adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment.LENVIMA (lenvatinib)
More news about: Eisai Inc.
May 05, 2026, 08:00 ET AVEO Oncology, an LG Chem company, Announces Two Poster Presentations at ASCO 2026 Annual Meeting
adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet
More news about: AVEO, an LG Chem company
Apr 15, 2026, 08:00 ET OncoHost to Present New Research on Proteomic Aging Biomarkers Outcomes at AACR 2026
renal cell carcinoma (RCC), and melanoma, alongside healthy controls. Results demonstrated that cancer patients exhibit significantly elevated biological age compared to healthy individuals, with lung age gap highest in NSCLC and SCLC, and kidney age gap most significant in RCC. In addition, organ-specific
More news about: OncoHost
Mar 13, 2026, 08:31 ET Retail & Hospitality ISAC and Retail Council of Canada Announce Strategic Partnership to Strengthen Cybersecurity Across Canadian Retail Sector
Retail Council of Canada (RCC) today announced a new strategic partnership aimed at bolstering the cybersecurity posture of retailers across Canada. This collaboration brings together
More news about: Retail & Hospitality ISAC
Mar 10, 2026, 15:21 ET Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment Adoption - Credence Research
https://www.credenceresearch.com/report/kidney-cancer-renal-cell-carcinoma-rcc-drugs-marketNovel Drug Delivery Systems in Cancer Therapy Market
More news about: Credence Research Inc.
Mar 10, 2026, 11:25 ET Celebrate MAR10 Day with Advance Tickets to an Early Showtime of The Super Mario Galaxy Movie at Regal
treats.Regal's loyalty members can power-up their moviegoing experience with multiple Super Mario Galaxy promotions. Regal Crown Club (RCC) and Unlimited members who secure advance tickets on MAR10 Day will find 1,000 bonus credits added to their accounts. Guests purchasing a can of bubly
More news about: Regal
Feb 26, 2026, 08:08 ET Eisai and Advocacy Leaders Launch "Kompass," a Digital Destination to Help Patients and Caregivers Navigate the Complexities of Kidney Cancer
about nine out of 10 kidney cancer diagnoses being RCC. In 2022, there were about 435,000 new cases of kidney cancer diagnosed and approximately 156,000 deaths from the disease worldwide. RCC is about twice as common in men as in women. Most cases of RCC are discovered incidentally during imaging tests
More news about: Eisai Inc.
Feb 24, 2026, 19:30 ET Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings. To date, JS207 has 11 ongoing phase II clinical studies, exploring
More news about: Antengene Corporation Limited
Feb 18, 2026, 09:00 ET AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study
adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet
More news about: AVEO, an LG Chem company
Feb 18, 2026, 07:00 ET PowerBank Appoints Andrew van Doorn as President & Chief Operating Officer
"Distribution Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), Research Capital Corporation ("RCC"), Research Capital USA Inc. (together with Wainwright and RCC, the "Agents") to renew the at-the-market equity program (the "ATM Program"). There can be no assurance
More news about: PowerBank Corporation
Feb 02, 2026, 17:31 ET TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with NSCLC, RCC, colorectal cancer, lung cancer, and many more indications; the growing awareness of TIGIT inhibitors; and the increasing number of emerging drugs such
More news about: DelveInsight Business Research, LLP
Jan 22, 2026, 12:30 ET Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
(non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally
More news about: Trevi Therapeutics, Inc.
Jan 14, 2026, 10:45 ET AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab
adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet
More news about: AVEO, an LG Chem company
Jan 08, 2026, 07:30 ET Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
(non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally
More news about: Trevi Therapeutics, Inc.